Chemo-and radio-therapeutic regimens frequently kill cancer cells by inducing apoptosis, a cell-death subroutine that involves the activation of a particular class of proteases called caspases. In a recent issue of Nature Medicine, Huang et al. (2011) show that caspase activation in dying tumor cells causes the release of soluble lipid messengers, notably prostaglandin E 2 , that stimulate tumor cell proliferation. In this short review, we will discuss the clinical and therapeutic implications of these findings.
Cells respond to stress, be it chemical (for example, cytotoxic agents) or physical (for example, irradiation) in a very heterogeneous fashion, meaning that rather different signaling cascades can be activated depending on both cell-intrinsic (for example, cell type, cell cycle phase) and cell-extrinsic parameters (for example, cell death stimulus, intensity of the stimulus, duration of the stimulus). This is particularly true for cancer cells that respond to chemo-and radio-therapeutic regimens in vivo as another layer of complexity is added by the intimate cross talk between the tumor and its microenvironment (Mueller and Fusenig, 2004) . Still, often (but not always) anticancer agents eventually kill tumor cells in vivo by inducing apoptosis, a cell-death modality that is characterized by peculiar morphological (Galluzzi et al., 2007; Kroemer et al., 2009) and biochemical features (Galluzzi et al., 2009a (Galluzzi et al., , 2011 . One of the most prominent molecular markers of apoptosis is constituted by the massive activation of a specific class of cysteine proteases, caspases, which have a prominent role in both the initiation (caspase-8 and -9) and the execution (caspase-3, -6 and -7) of the apoptotic program, especially when this is induced by extracellular signals (Galluzzi et al., 2009a (Galluzzi et al., , 2011 . Indeed, intrinsic apoptosis (that is, apoptosis ignited by intracellular stress conditions) can also occur independently of caspase activation (Kroemer and Martin, 2005; Tait and Green, 2008) .
Caspases are not only involved in the execution of cell death, but they also participate in multiple physiological, cell death-unrelated processes (Kang et al., 2004; Launay et al., 2005; Galluzzi et al., 2008) . For instance, caspase-3 contributes to the differentiation of several cell types, including granulocytes, erythroblasts, platelets, osteoblasts, as well as sperm, muscle and trophoblast cells. Along similar lines, it has become clear that caspase-8 mediates critical pro-survival functions, as exemplified by the fact that Casp8 À/À mice die between embryonic days 10.5 and 11.5 unless the pro-necrotic receptor-interacting protein kinase 3 (RIPK3) (Vandenabeele et al., 2010) is also deleted (Kaiser et al., 2011) . Still, all caspase-targeted therapeutic interventions that have been envisioned so far were aimed at inhibiting caspase activation to limit the loss of post-mitotic cells, for instance in the context of stroke and trauma (Galluzzi et al., 2009b, c) .
Chuan-Yuan Li's lab recently reported that, in cancer and stromal cells undergoing radiotherapy-induced apoptosis, caspase-3 not only mediates cell death, but also elicits a signaling cascade that eventually stimulates the growth of tumor cells that resist therapy. To test the hypothesis that dying cells in the tumor mass may provide the initial signals to promote tumor repopulation, Huang et al. used luciferaselabeled mouse breast cancer 4T1 cells and monitored their growth in vitro and in vivo (in mice, by means of the bioluminescence tomography technology) in the presence of unlabeled cells of the same type that were left untreated or subjected to lethal doses of X-rays. Dying but not live unlabeled cells consistently supported the proliferation of labeled cells, and this phenomenon was not cell type-specific, as these observations could be extended to human breast cancer and colorectal carcinoma cells (Huang et al., 2011) . The authors reasoned that one of the evolutionarily conserved processes that mediate cell death might also be responsible for the generation of a mitogenic signal. To investigate this hypothesis, Huang et al. took advantage of Casp3 À/À mouse embryonic fibroblasts (Kuida et al., 1996; Lakhani et al., 2006) and of a dominant-negative version of caspase-3 (C163A) (Stennicke and Sal-vesen, 1997) . Proteolytically active caspase-3 was required for dying cells to sustain the growth of cancer cells, in vitro and in vivo. In line with these observations, chemical blockage of caspase-3 with a broad spectrum caspase inhibitor, Z-VAD-fmk, abrogated the mitogenic potential of lethally irradiated cells (Huang et al., 2011) . Moreover, luciferase-labeled cancer cells injected into pre-established, irradiated tumors were found to preferentially grow in the proximity of caspase-3 activation sites, as determined by a green fluorescent protein-based caspase-3 reporter (Huang et al., 2011) . Taken together, these observations indicate that tumor and stromal cells succumbing to radiotherapy emit a mitogenic signal as a result of caspase-3 activation.
Huang et al. then moved one step further and characterized the nature of such a mitogenic signal. As it was previously known that the cytosolic Ca 2 þ -independent phospholipase A 2 (iPLA 2 , encoded by the PLA2G6 gene) is activated by caspase-3-mediated proteolysis (Atsumi et al., 1998; Lauber et al., 2003; Zhao et al., 2006) , the authors compared dying iPLA 2 -deficient and iPLA 2 -proficient 4T1 cells for their ability to sustain cell proliferation in vitro and in vivo (Huang et al., 2011) . iPLA 2 was required for the emission of mitogenic signals from dying cells. Accordingly, arachidonic acid (AA), one of the major products of iPLA 2 , was released into the supernatant of dying cells in a caspase-3-dependent fashion, prompting Huang and colleagues to focus their attention on prostaglandin E 2 (PGE 2 ), a downstream product of AA. Similar to its precursor, PGE 2 was liberated by wild-type cells succumbing to irradiation, but not by their caspase-3-deficient counterparts. Moreover, while indomethacin (an inhibitor of cyclooxygenases, that is, the enzymes that convert iPLA 2 -generated AA into prostaglandins) effectively suppressed the growth of cancer cells injected into previously irradiated tumors, the administration of PGE 2 recapitulated the mitogenic properties of lethally irradiated cells in vivo. In line with these observations, depletion of the main PGE 2 receptor (EP 2 ) from 4T1 cells reduced their sensitivity to growth stimulation by dying cells (Huang et al., 2011) . Taken together, these findings suggest that radiotherapy-induced caspase-3 activation stimulates the catalytic activity of iPLA 2 , resulting in PGE 2 -driven cancer cell proliferation.
Finally, in one cohort of head and neck cancer patients treated with radiotherapy and in one cohort of untreated advanced breast cancer patients, Huang and colleagues could correlate high levels of caspase-3 activation (in the tumor) with recurrence and shorter survival rates, respectively (Huang et al., 2011) . These results strongly suggest that caspase-3 activation may constitute a negative prognostic factor in human malignancies.
The molecular mechanisms by which PGE 2 (and possibly other iPLA 2 -related products) released by dying cells would stimulate the proliferation of residual tumor cells remain poorly understood. PGE 2 binds to a G-protein-coupled receptor of 53 kDa (EP 2 ) (Regan, 2003) and has previously been shown to activate the WNT-b-catenin signaling pathway (Castellone et al., 2005; Goessling et al., 2009 ), a proto- Figure 1 Caspase-dependent apoptosis favors the proliferation of tumor cells that escape therapy and the emergence of resistant tumors. In response to chemo-and radiotherapy, a sizeable fraction of cancer cells as well as cells from the tumor stroma undergo apoptosis, a cell-death modality that frequently involves the activation of a particular class of proteases called caspases. However, active caspase-3 (Casp-3) not only mediates cell death, but also proteolytically activates the cytosolic Ca 2 þ -independent phospholipase A 2 (iPLA 2 ), an enzyme that generates arachidonic acid (AA) by using plasma membrane phospholipids (PLs) as substrates. AA can be sequentially processed by cyclooxygenases 1 and 2 (COX1/2), prostaglandin H 2 synthase (PGHS) and PGE 2 synthase (PGES), leading to the generation and release of PGE 2 . In turn, PGE 2 fixes G-protein-coupled receptors (EP 2 ) expressed on the surface of tumor cells, thereby stimulating their proliferation perhaps by the WNT-b-catenin signaling pathway. In this context, blocking caspase-3 (with the broad spectrum caspase inhibitor Z-VAD-fmk), inhibiting the PGE 2 biosynthetic pathway (for instance with the COX1/2 inhibitor indomethacin, Indo) and/or interfering with the PGE 2 -EP 2 interaction might prevent the recurrence of therapy-resistant tumors and result in significant therapeutic advantages.
Cell death-induced proliferation of cancer L Galluzzi et al oncogenic signaling cascade that is involved in the regulation of multiple intracellular processes, including cell proliferation (Angers and Moon, 2009 ). Huang and colleagues did not directly address this possibility and hence, it cannot be formally excluded that the proproliferative effects of PGE 2 are mediated by signal transducers other than WNT and b-catenin.
Irrespective of these incognita, recent results from four, very large randomized trials show that the long-term consumption of aspirin (another non-selective cyclooxygenase inhibitor) at doses of at least 75 mg/day reduces long-term incidence and mortality due to cancers of the proximal colon (Rothwell et al., 2010) . This corroborates the notion that prostaglandin-mediated signaling exerts-at least in a specific setting-tumorigenic effects.
Of note, the phenomenon of dying cell-stimulated cell proliferation has also been observed in model organisms including Drosophyla melanogaster and hydra (Ryoo et al., 2004; Fan and Bergmann, 2008; Chera et al., 2009) , and may therefore constitute an evolutionarily ancient mechanism for tissue regeneration that cancer cells can hijack at their own benefit (Li et al., 2010) . Thus, the results reported by Huang et al. describe a therapeutic nightmare, as the interventions that intend to destroy the tumor exert a paradoxical effect. Indeed, while a fraction of malignant or stromal cells succumb to ionizing irradiation, they emit mitogenic signals that stimulate the growth of their resistant neighbors, thus annihilating the therapeutic effect and favoring the Darwinian selection of ever more resistant and genomically unstable tumor cells.
Is there a way out of the dilemma? Theoretically, caspase inhibitors, chemicals that block prostaglandin synthesis (for example, inhibitors of cyclooxygenases) as well as inhibitors of prostaglandin receptors might be used in combination with conventional anticancer agents for limiting the proliferation of therapy-resistant cells and hence avoiding tumor recurrence (Figure 1) . In addition, the results from Huang and colleagues suggest that apoptotic cell death may not always constitute a therapeutically desirable endpoint and that chemicals that induce alternative cell-death modalities, including mitotic catastrophe and regulated necrosis, (Vandenabeele et al., 2010; Galluzzi et al., 2011; Vitale et al., 2011) might constitute valuable therapeutic tools. Future work will clarify if and which one among these possible approaches will provide actual benefits to cancer patients.
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